Patents by Inventor Christoph Schaab

Christoph Schaab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Markers for susceptibility to an inhibitor of an Src-family kinase
    Patent number: 9328386
    Abstract: The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the Src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the Src family, whereby the individual is suspected to suffer from cancer. These methods involve the evaluation of the status of integrin ?4, wherein said status is indicative for the responsiveness to the inhibitor. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo—or polynucleotide and/or antibodies capable of detecting the expression level of integrin ?4 for predicting the responsiveness to the inhibitor are provided.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 3, 2016
    Assignee: Evotec (München) GmbH
    Inventors: Christoph Schaab, Klaus Godl, Martin Klammer, Andreas Tebbe, Stefan Müller
  • MARKERS FOR SUSCEPTIBILITY TO AN INHIBITOR OF AN SRC-FAMILY KINASE
    Publication number: 20140302172
    Abstract: The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the Src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the Src family, whereby the individual is suspected to suffer from cancer. These methods involve the evaluation of the status of integrin ?4, wherein said status is indicative for the responsiveness to the inhibitor. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide and/or antibodies capable of detecting the expression level of integrin ?4 for predicting the responsiveness to the inhibitor are provided.
    Type: Application
    Filed: August 16, 2012
    Publication date: October 9, 2014
    Inventors: Christoph Schaab, Klaus Godl, Martin Klammer, Andreas Tebbe, Stefan Müller
  • Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and EGFR inhibitors or pyrimidine analogues
    Patent number: 8048888
    Abstract: The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: November 1, 2011
    Assignee: Agennix AG
    Inventors: Katja Wosikowski-Buters, Christoph Schaab, Marino Schuhmacher, Franz Obermayr, Igor Ivanov
  • Anti-Proliferative Combination Therapy Using Certain Platinum-Based Chemotherapeutic Agents and EGFR Inhibitors or Pyrimidine Analogues
    Publication number: 20090175856
    Abstract: The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 9, 2009
    Inventors: Katja Wosikowski-Buters, Christoph Schaab, Marino Schuhmacher, Franz Obermayr, Igor Ivanov